IBM is reportedly in advanced talks to acquire Confluent, a leading data infrastructure company, for approximately $11 billion, signaling a significant step in its cloud expansion strategy. Confluent’s open-source platform enables businesses to process vast streams of real-time data, ranging from financial transactions to website activity, making it a key asset in today’s data-driven economy. The acquisition, which could be announced imminently, reflects IBM’s efforts to strengthen its cloud software offerings amid rising demand for artificial intelligence and data infrastructure solutions. Under CEO Arvind Krishna, IBM has increasingly prioritized software and cloud services, following prior acquisitions like HashiCorp. This move…
Author: John
Indian pharmaceutical tycoon Kiran Mazumdar-Shaw has taken a decisive step to strengthen Biocon’s global ambitions by fully consolidating Biocon Biologics in a landmark $5.5 billion buyout. The transaction brings Biocon’s biosimilars and generics businesses under a unified corporate structure, reinforcing its position as a major force in the international biopharmaceutical industry. By acquiring the remaining shares from financial and strategic investors, Biocon aims to simplify operations, improve capital efficiency, and sharpen its focus on high-growth therapeutic areas such as diabetes, oncology, and immunology. The move reflects Mazumdar-Shaw’s long-term strategy to build a globally competitive healthcare company capable of delivering affordable,…